Trending Stories
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - Trump 2016: A look back at the 45th president’s impact on oncology
- At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS
- A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment - How the 2024 elections can impact cancer policy
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
